Genmab reported strong first-half results driven by DARZALEX sales reaching $8.17 billion, already surpassing half of its $16 billion full-year sales target. If second-half sales remain steady, total sales could hit $16.59 billion, exceeding the high end of guidance. DARZALEX royalties are expected to increase from 14.2% in Q1 to about 16.9% for the year. However, risks include high valuation, reliance on DARZALEX, significant net debt, weak cash conversion, and pipeline uncertainties.
The global pharmaceutical surfactants market, valued at $4.5 billion in 2025, is projected to grow to $6.93 billion by 2035 at a CAGR of 4.42%. Growth is fueled by increasing use in drug formulation to enhance solubility, stability, and bioavailabili...
POSCO International and LG CNS have launched a pilot project to tokenize live trade receivables from over 80 global subsidiaries on the Injective blockchain. This initiative aims to streamline reconciliation and accelerate cash access by using a shar...
VinFast has formed a strategic partnership with akf-Bank to provide tailored financing solutions for its dealers across Germany, enhancing their ability to finance vehicle inventory and support sales to private and fleet customers. This collaboration...
Crypto analyst Ali Martinez predicts Dogecoin could gain up to 150% if it breaks the key resistance level at $0.081. This breakout could lead the price toward $0.177, the next significant supply zone. Technical indicators like MACD show a buy signal,...
Stellantis has agreed to sell its Free2move car-sharing business to Mutares, with the transaction expected to close by the end of 2026. Free2move operates free-floating car-sharing services across 14 cities in Europe and the U.S. This sale aligns wit...
